Baxalta Gmbh

Baxter International Inc.

Takeda Pharmaceutical Company Limited

Baxter Healthcare Sa

Children's Medical Center Corporation

Baxter Aktiengesellschaft

Baxter Health S.a.

The Cbr Institute for Biomedical Research, Inc.

Barbara Plaimauer

Friedrich Scheiflinger

Hanspeter Rottensteiner

Eva-Maria Muchitsch

Alexandra Nathalie Kopic

Denisa D Wagner

Manfred Rieger

Werner Höllriegl

Anil Kumar Chauhan

Manfred Reiter

Artur Mitterer

Leopold Grillberger

Meinhard Hasslacher

Uwe Schlokat

Gerhard Antoine

Simone Von Fircks

Werner Hoellriegl

Roland Geyer

Silvia Ferrari

Bernadette Gruber

Denisa Wagner

This invention relates to methods of subcutaneous administration of ADAMTS13 formulations to a treat a disease or condition associated with ADAMTS13 and VWF dysfunction. Furthermore, evidence of the unexpectedly high bioavailability of ADAMTS13 formulations administered subcutaneously is provided herein.

Subcutaneous administration of ADAMTS13

This invention relates to a pharmaceutical composition having thrombolytic activity comprising ADAMTS13, and to methods for treating or preventing a disorder associated with the formation and/or the presence of one or more thrombus and to methods of disintegrating one or more thrombus in a patient in need thereof. Furthermore, the invention relates to the use of a pharmaceutically effective amount of ADAMTS13 for the preparation of a pharmaceutical composition for treating or preventing a disorder associated with the formation or the presence of one or more thrombus and for disintegrating one or more thrombus in a patient in need thereof.

ADAMTS13-containing compositions having thrombolytic activity

The present invention relates to recombinant furin (rFurin) and methods for producing rFurin. More specifically, the invention relates to substantially animal protein-free rFurin and methods for producing substantially animal protein-free rFurin.

Substantially animal protein-free recombinant furin and methods for producing the same

This invention relates to adsorbents and methods for highly selective removal of anti-von Willebrand Factor-cleaving protease antibodies ('anti-vWF-cp-abs') from human plasma using human von Willebrand Factor-cleaving protease ('hvWF-cp') or fragments thereof as affinity ligands. The adsorbents can be used for treating disorders associated with the occurrence of anti-vWF-cp-abs in patients, such as thromboembolic diseases.

Immunoadsorption of anti-von Willebrand factor cleaving protease antibodies

This invention relates to a kit to be used in an assay system for determination of an anti-von Willebrand Factor-cleaving protease ('anti-vWF-cp') antibody in a sample. The kit comprises vWF-cp and/or vWF-fragment(s) immobilized on a solid phase. The kit can be used in a method for determination of anti-vWF-cp antibodies from a patient, for the diagnosis of disorders associated with the occurrence of anti-vWF-cp-antibodies, and the differentiation of various forms of thrombotic microangiopathy.

Diagnostic assay for anti-von Willebrand Factor cleaving protease (ADAMTS13) antibodies

The present invention comprises a furin polypeptide having a modified amino acid sequence between the middle, homo-B-domain and the transmembrane domain compared to wild-type furin which retains proteolytic activity but is secreted at lower levels in cell culture compared to wild-type furin. Additionally, the invention includes nucleic acid molecules encoding such furin polypeptides, vectors and host cells comprising said nucleic acid molecules, compositions comprising said furin polypeptide and methods for producing such compositions.

Furin polypeptides with improved characteristics

Growing community of inventors

Vienna, Austria

Barbara Plaimauer